Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Swati Menthol And Allied Chemicals Pvt Ltd

    Swati Menthol & Allied Chemicals Ltd (SMACL) is engaged in manufacturing of Menthol and allied products and Pine and Aroma chemicals such as natural menthol, essential oil, pepp

  • No Image
    Swiss Formulations

    Swiss Formulations (India) is engaged in manufacturing and exporting of high quality inorganic and fine chemicals. It produces premium Magnesium Carbonate. Established in the ye

  • No Image
    Symbiosis Pharmaceuticals Pvt Ltd

    Symbiosis Pharmaceuticals Pvt Ltd was incorporated at Kala Amb, Himachal Pradesh, in the year 2003. The company is involved in the manufacturing of generic drugs in various form